WILMINGTON, Del., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Fitbit, Inc. (NYSE:FIT)?
- Did you purchase your shares pursuant and/or traceable to the June 18, 2015 initial public offering, or between June 18, 2015 and January 6, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. announces that a complaint has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities that purchased the common stock of Fitbit, Inc. (“Fitbit” or the “Company”) (NYSE:FIT) between June 18, 2015 and January 6, 2016, inclusive, including those investors who acquired Fitbit shares pursuant or traceable to its initial public offering (“IPO”) commenced on or about June 18, 2015 (collectively, the “Class Period), alleging violations of the Securities Exchange Act of 1933 and the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you purchased shares of Fitbit in the June 18, 2015 offering, or during the period June 18, 2015 and January 11, 2016, inclusive, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/fitbit-inc-fit-lawsuit.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
According to the Complaint, on January 5, 2016, a class action lawsuit was reported as filed against Fitbit alleging that the heart rate monitoring systems on the Company’s Charge HR and Surge devices were dangerously inaccurate and posed serious health risks to users. The claims against Fitbit include violations of California’s Unfair Competition Law and Consumers Legal Remedies Act, common law fraud, and unjust enrichment.
On this news, shares in Fitbit dropped over 18%, closing at $24.30 per share on January 5, 2016, on heavy trading volume.
If you wish to serve as lead plaintiff, you must move the Court no later than March 11, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com


Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
First Western Ship Transits Strait of Hormuz Since Iran War Began
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Britain Courts Anthropic Amid US Defense Department Dispute 



